Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Remon

Showing results (21-30 of 184) with videos related to

Pageof 19
Sort By:
Atencion Primaria|February 9, 2007
[Complementary medicines in oncology]Jordi Remon Masip, Pilar Lianes Barragán
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2023
First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?Dipesh Uprety, Jordi Remon, Solange Peters
The European Respiratory Journal|May 2, 2016
The 5000% case: a glimpse into the financial issue of lung cancer treatmentJordi Remon, Julia Bonastre, Benjamin Besse
Mediastinum (Hong Kong, China)|February 4, 2022
Targeted therapies for unresectable stage III non-small cell lung cancerJordi Remon, Lizza E L Hendriks
Translational Lung Cancer Research|May 13, 2024
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinibBoris Duchemann, Emmanuelle Fabre, Jordi Remon
Lancet (London, England)|May 29, 2026
Redefining first-line standards with new partnersStephanie P L Saw, Jordi Remon
Translational Cancer Research|February 4, 2022
CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancerJordi Remon, Ana Collazo, Beatriz Jimenez
Translational Lung Cancer Research|July 23, 2021
Immunotherapy in malignant pleural mesothelioma: a review of literature dataJessica Menis, Giulia Pasello, Jordi Remon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2026
BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung CancerJordi Remon, Tina Cascone, Solange Peters
Future Oncology (London, England)|May 16, 2020
Combination treatments with immunotherapy in brain metastases patientsClemence Henon, Jordi Remon, Lizza El Hendriks
Pageof 19

Showing results (21-30 of 184) with videos related to

Sort By:
Pageof 19
Atencion Primaria|February 9, 2007
[Complementary medicines in oncology]Jordi Remon Masip, Pilar Lianes Barragán
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2023
First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?Dipesh Uprety, Jordi Remon, Solange Peters
The European Respiratory Journal|May 2, 2016
The 5000% case: a glimpse into the financial issue of lung cancer treatmentJordi Remon, Julia Bonastre, Benjamin Besse
Mediastinum (Hong Kong, China)|February 4, 2022
Targeted therapies for unresectable stage III non-small cell lung cancerJordi Remon, Lizza E L Hendriks
Translational Lung Cancer Research|May 13, 2024
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinibBoris Duchemann, Emmanuelle Fabre, Jordi Remon
Lancet (London, England)|May 29, 2026
Redefining first-line standards with new partnersStephanie P L Saw, Jordi Remon
Translational Cancer Research|February 4, 2022
CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancerJordi Remon, Ana Collazo, Beatriz Jimenez
Translational Lung Cancer Research|July 23, 2021
Immunotherapy in malignant pleural mesothelioma: a review of literature dataJessica Menis, Giulia Pasello, Jordi Remon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2026
BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung CancerJordi Remon, Tina Cascone, Solange Peters
Future Oncology (London, England)|May 16, 2020
Combination treatments with immunotherapy in brain metastases patientsClemence Henon, Jordi Remon, Lizza El Hendriks
Pageof 19